Baxter International develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operates through three segments: BioScience, Medication Delivery, and Renal. It offers peritoneal dialysis and hemodialysis, renal replacement therapies and other organ support therapies, sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, drug reconstitution devices, and parenteral nutrition therapies.
Type
Public
HQ
Deerfield, US
Founded
1931
Size (employees)
47,000 (est)-2%
Website
baxter.com
Baxter International was founded in 1931 and is headquartered in Deerfield, US
Report incorrect company information

Key People/Management at Baxter International

José Almeida

José Almeida

Chairman, President and Chief Executive Officer
John Forsyth

John Forsyth

Chairman and Chief Executive Officer, Wellmark Blue Cross and Blue Shield
James Gavin

James Gavin

Chief Executive Officer and Chief Medical Officer, Healing Our Village, Inc
Munib Islam

Munib Islam

Partner and Head of Equities Research, Third Point LLC
Michael Mahoney

Michael Mahoney

Chairman, President and Chief Executive Officer, Boston Scientific Corporation
Cathy Smith

Cathy Smith

Executive Vice President and Chief Financial Officer, Target Corporation
Show more

Baxter International Office Locations

Baxter International has offices in Lombard, Houston, Baltimore, Bloomington and in 34 other locations
Deerfield, US (HQ)
One Baxter Parkway
Show all (38)
Report incorrect company information

Baxter International Financials and Metrics

Baxter International Financials

Baxter International's revenue was reported to be $10.16 b in FY, 2016 which is a 2% increase from the previous period.
USD

Revenue (Q2, 2017)

2.6 b

Gross profit (Q2, 2017)

1.1 b

Gross profit margin (Q2, 2017), %

43.4%

Net income (Q2, 2017)

265 m

EBIT (Q2, 2017)

339 m

Market capitalization (20-Apr-2018)

37.2 b

Cash (30-Jun-2017)

3.8 b
Baxter International's current market capitalization is $37.2 b.
Annual
USDFY, 2015FY, 2016

Revenue

10 b10.2 b

Revenue growth, %

(40%)2%

Cost of goods sold

5.8 b6.1 b

Gross profit

4.1 b4.1 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

3.8 b4 b4.3 b4.2 b3.8 b3.9 b2.5 b2.4 b2.6 b2.6 b2.5 b2.6 b

Cost of goods sold

1.8 b2 b2.2 b2.1 b2 b2 b1.5 b1.4 b1.6 b1.5 b1.4 b1.5 b

Gross profit

1.9 b2 b2 b2.1 b1.8 b1.9 b1 b965 m972 m1.1 b1 b1.1 b

Gross profit Margin, %

52%50%48%49%48%49%42%41%38%42%42%43%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.7 b2.9 b2.2 b2.8 b

Inventories

3.5 b3.6 b1.6 b1.4 b

Current Assets

10 b10.4 b11.8 b6.6 b

PP&E

7.8 b8.7 b4.4 b4.3 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

2.4 b2 b1.9 b2.1 b2.5 b6.7 b2 b2.2 b2.6 b2.6 b2.9 b3.8 b

Inventories

3.6 b3.7 b3.8 b3.7 b3.5 b3.8 b1.7 b1.7 b1.6 b1.6 b1.5 b1.5 b

Current Assets

9.6 b9.4 b9.5 b9.6 b9.7 b14.5 b11.1 b8 b6.8 b6.6 b6.6 b7.7 b

PP&E

7.5 b8 b8.2 b8.4 b8.5 b9 b4.3 b4.4 b4.3 b4.3 b4.3 b4.3 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

2 b2.5 b968 m5 b

Inventories

(311 m)(439 m)1.6 b80 m

Cash From Operating Activities

2.2 b3.2 b1.8 b1.7 b

Cash From Investing Activities

5.4 b(1.5 b)(1.8 b)(715 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

544 m556 m520 m468 m430 m762 m763 m3.4 b4.6 b4.7 b272 m537 m

Depreciation and Amortization

497 m593 m189 m395 m599 m194 m378 m

Inventories

(439 m)(205 m)(26 m)(25 m)(11 m)(29 m)(38 m)

Income Taxes Paid

429 m345 m453 m
USDY, 2017

Revenue/Employee

54.3 k

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information